CN106232831B - 通过表达谱分析对淋巴瘤类型进行亚型分类的方法 - Google Patents

通过表达谱分析对淋巴瘤类型进行亚型分类的方法 Download PDF

Info

Publication number
CN106232831B
CN106232831B CN201480072382.7A CN201480072382A CN106232831B CN 106232831 B CN106232831 B CN 106232831B CN 201480072382 A CN201480072382 A CN 201480072382A CN 106232831 B CN106232831 B CN 106232831B
Authority
CN
China
Prior art keywords
gene expression
dlbcl
genbank accession
sample
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480072382.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106232831A (zh
Inventor
路易斯·M·施陶特
乔治·W·赖特
戴维·威廉·斯科特
约瑟夫·M·康纳斯
兰迪·D·加斯科因
莉萨·里姆萨
埃利亚斯·坎波圭里
雷蒙德·塔布斯
蒂莫西·C·格雷纳
詹姆斯·罗伯特·库克
傅凯
保罗·迈克尔·威廉姆斯
栗志坚
伊莱恩·S·贾菲
丽塔·M·布拉齐耶尔
安德烈亚斯·罗森瓦尔德
埃伦德·B·什梅兰德
荣·C·陈
格尔曼·奥特
扬·德拉比
丹尼斯·魏森贝格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Columbia Cancer Agency BCCA
Julius Maximilians Universitaet Wuerzburg
Universitat de Barcelona UB
Hospital Clinic de Barcelona
Oslo Universitetssykehus hf
Cleveland Clinic Foundation
Oregon Health and Science University
University of Nebraska System
Arizona's Public Universities
US Department of Health and Human Services
Original Assignee
British Columbia Cancer Agency BCCA
Julius Maximilians Universitaet Wuerzburg
Universitat de Barcelona UB
Hospital Clinic de Barcelona
Oslo Universitetssykehus hf
Cleveland Clinic Foundation
Oregon Health and Science University
University of Nebraska System
Arizona's Public Universities
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency BCCA, Julius Maximilians Universitaet Wuerzburg, Universitat de Barcelona UB, Hospital Clinic de Barcelona, Oslo Universitetssykehus hf, Cleveland Clinic Foundation, Oregon Health and Science University, University of Nebraska System, Arizona's Public Universities, US Department of Health and Human Services filed Critical British Columbia Cancer Agency BCCA
Publication of CN106232831A publication Critical patent/CN106232831A/zh
Application granted granted Critical
Publication of CN106232831B publication Critical patent/CN106232831B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480072382.7A 2013-11-06 2014-11-05 通过表达谱分析对淋巴瘤类型进行亚型分类的方法 Active CN106232831B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361900553P 2013-11-06 2013-11-06
US61/900,553 2013-11-06
PCT/US2014/064161 WO2015069790A1 (en) 2013-11-06 2014-11-05 Method for subtyping lymphoma types by means expression profiling

Publications (2)

Publication Number Publication Date
CN106232831A CN106232831A (zh) 2016-12-14
CN106232831B true CN106232831B (zh) 2021-02-26

Family

ID=51987470

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480072382.7A Active CN106232831B (zh) 2013-11-06 2014-11-05 通过表达谱分析对淋巴瘤类型进行亚型分类的方法

Country Status (9)

Country Link
US (2) US10607717B2 (https=)
EP (2) EP3066215B1 (https=)
JP (2) JP6657105B2 (https=)
KR (1) KR102357699B1 (https=)
CN (1) CN106232831B (https=)
AU (1) AU2014346788B8 (https=)
CA (1) CA2929826C (https=)
ES (2) ES2923942T3 (https=)
WO (1) WO2015069790A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
WO2016168667A1 (en) * 2015-04-16 2016-10-20 Offender Smartphone Monitoring, LLC Monitoring process
US20240430385A1 (en) * 2015-04-16 2024-12-26 Offender Smartphone Monitoring, LLC Monitoring process
JP6969848B2 (ja) 2015-07-13 2021-11-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
WO2017059108A1 (en) * 2015-09-29 2017-04-06 Htg Molecular Diagnostics, Inc. Methods for subtyping diffuse b-cell lymphoma (dlbcl)
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
JP7075896B2 (ja) * 2016-04-20 2022-05-26 アメリカ合衆国 マントル細胞リンパ腫の評価及びそれに関連する方法
US9963748B2 (en) 2016-05-13 2018-05-08 Roche Molecular Systems, Inc. Methods and compositions for classifying DLBCL
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
US11696250B2 (en) * 2016-11-09 2023-07-04 Intel Corporation UE and devices for detach handling
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
EP3638814B8 (en) 2017-06-14 2023-06-21 The United States of America, as Represented by The Secretary, Department of Health and Human Services Method for determining lymphoma type
IL272418B2 (en) * 2017-08-08 2024-09-01 Hoffmann La Roche Abinotuzumab treatment of a new subgroup of DLBCL patients
JP7517983B2 (ja) * 2017-11-20 2024-07-17 ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク 非常に低レベルのｃｄ１９を発現する骨髄腫細胞を除去するｃｄ１９ｃａｒｔ細胞
EP3719127A4 (en) 2017-12-01 2021-10-20 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
EP3719126B1 (en) 2017-12-01 2025-01-01 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
DK3719128T3 (da) 2017-12-01 2025-03-03 Suzhou Ribo Life Science Co Ltd Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf
CA3083970A1 (en) 2017-12-01 2019-06-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
AU2018394875B2 (en) 2017-12-29 2023-08-03 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
ES3016786T3 (en) * 2018-08-01 2025-05-09 Genentech Inc Prediction and characterization of dlbcl cell of origin subtypes
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020079591A1 (en) * 2018-10-15 2020-04-23 Provincial Health Services Authority Gene expression profiles for b-cell lymphoma and uses thereof
JP2022513038A (ja) * 2018-11-14 2022-02-07 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合薬を使用する癌の治療方法
WO2020135673A1 (zh) 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CA3131874A1 (en) * 2019-03-28 2020-10-01 Philippe RUMINY Classification of b-cell non-hodgkin lymphomas
CN111850114A (zh) * 2019-04-25 2020-10-30 上海交通大学医学院附属瑞金医院 一组用于评估弥漫大b细胞淋巴瘤分子分型的基因群，其试剂盒及分析方法
AU2020280439B2 (en) 2019-05-22 2025-08-14 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US12590304B2 (en) 2019-05-22 2026-03-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
JP7606758B2 (ja) * 2019-05-22 2024-12-26 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
KR20220011689A (ko) 2019-05-22 2022-01-28 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도
CN113795582B (zh) 2019-05-24 2024-05-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
US20220259667A1 (en) * 2019-07-22 2022-08-18 Roche Sequencing Solutions, Inc. Systems and methods for cell of origin determination from variant calling data
CA3148611A1 (en) 2019-08-12 2021-02-18 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
CN111621565B (zh) * 2020-05-07 2023-12-15 杭州可帮基因科技有限公司 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置
CN111785370B (zh) * 2020-07-01 2024-05-17 医渡云（北京）技术有限公司 病历数据处理方法及装置、计算机存储介质、电子设备
EP4736878A2 (en) * 2020-07-08 2026-05-06 pharma& Schweiz GmbH Satraplatin for use in the treatment of lymphoid neoplasms
JP2023536900A (ja) * 2020-08-05 2023-08-30 ティアークリアー コープ． 眼科用製剤からの防腐剤除去のためのシステムおよび方法
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN113186289B (zh) * 2021-05-12 2023-02-24 清华大学深圳国际研究生院 lncRNA在肾癌尿液筛查和肾癌治疗中的应用
CN119842823A (zh) * 2024-12-25 2025-04-18 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） SLC35E2B在Hacat细胞模型构建中的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5252743A (en) 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
EP0834575B1 (en) 1990-12-06 2001-11-28 Affymetrix, Inc. (a Delaware Corporation) Identification of nucleic acids in samples
US5770358A (en) 1991-09-18 1998-06-23 Affymax Technologies N.V. Tagged synthetic oligomer libraries
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5550215A (en) 1991-11-22 1996-08-27 Holmes; Christopher P. Polymer reversal on solid surfaces
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US6090555A (en) 1997-12-11 2000-07-18 Affymetrix, Inc. Scanned image alignment systems and methods
EP0758403B1 (en) 1994-05-05 1998-06-24 Beckman Instruments, Inc. Oligonucleotide repeat arrays
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
EP0902885A4 (en) 1996-05-16 2006-09-27 Affymetrix Inc SYSTEMS AND METHODS FOR DETECTION OF BRANDED PRODUCTS
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US5936324A (en) 1998-03-30 1999-08-10 Genetic Microsystems Inc. Moving magnet scanner
US6020198A (en) 1998-09-25 2000-02-01 Isis Pharmaceuticals Inc. Antisense modulation of RIP-1 expression
EP1339872A2 (en) 2000-09-19 2003-09-03 Whitehead Institute For Biomedical Research Genetic markers for tumors
US20030194701A1 (en) 2000-11-20 2003-10-16 Golub Todd R. Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
EP1436283B1 (en) 2001-09-21 2008-01-23 Boryung Pharmaceutical Co., Ltd. Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
ES2542328T3 (es) 2002-12-06 2015-08-04 Millennium Pharmaceuticals, Inc. Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
PT1660458E (pt) 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
US20110152115A1 (en) 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
EP1664762A4 (en) * 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA
WO2005082415A2 (en) 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
EP1805197A1 (en) 2004-09-27 2007-07-11 Med Biogene Inc Hematological cancer profiling system
AU2006234897A1 (en) 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
CN101910414B (zh) * 2007-11-07 2016-01-13 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
WO2011009104A1 (en) * 2009-07-16 2011-01-20 The General Hospital Corporation Nucleic acid analysis
KR101810799B1 (ko) 2008-02-01 2017-12-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
US20110195064A1 (en) 2008-06-06 2011-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Survival predictor for diffuse large b cell lymphoma
ES2352777B1 (es) 2009-07-31 2012-01-23 Hospital Clinic De Barcelona Metodo y kit para el pronostico del linfoma de celulas del manto
CA3061784C (en) * 2009-11-13 2023-09-26 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
US20130058863A1 (en) * 2010-02-04 2013-03-07 Jake Yue Chen 4-Protein Biomarker Panel for the Diagnosis of Lymphoma from Biospecimen
US20110293629A1 (en) * 2010-05-14 2011-12-01 Bastid Jeremy Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
CA3007787C (en) * 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US20120258878A1 (en) 2010-08-04 2012-10-11 Med Biogene Inc. Prognostic gene signatures for non-small cell lung cancer
AU2012249491B2 (en) * 2011-04-29 2016-12-15 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
US20140303034A1 (en) 2011-12-09 2014-10-09 British Columbia Cancer Agency Branch Predicting prognosis in classic hodgkin lymphoma
CA2864161A1 (en) 2012-02-10 2013-08-15 Whitehead Institute For Biomedical Research Inhibition of the glycine cleavage system for treatment of cancer
US9803245B2 (en) 2012-03-14 2017-10-31 University Health Network Signature for predicting clinical outcome in human HER2+ breast cancer
US9890430B2 (en) 2012-06-12 2018-02-13 Washington University Copy number aberration driven endocrine response gene signature
WO2014197936A1 (en) 2013-06-14 2014-12-18 The State Of Queensland Acting Through Its Department Of Health Biomarkers and use thereof in identification of b-cell lymphoproliferative disorders
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma;George Wright等;《PNAS》;20030819;第100卷(第17期);第9991–9996页 *
Germinal Center B Cell-Like (GCB) and Activated B Cell-Like (ABC) Type of Diffuse Large B Cell Lymphoma (DLBCL): Analysis of Molecular Predictors, Signatures, Cell Cycle State and Patient Survival;S. Blenk等;《Cancer Informatics》;20071231;第3卷;第399–420页 *

Also Published As

Publication number Publication date
US20200143906A1 (en) 2020-05-07
JP2020078323A (ja) 2020-05-28
ES2923942T3 (es) 2022-10-03
EP3066215A1 (en) 2016-09-14
US10607717B2 (en) 2020-03-31
CN106232831A (zh) 2016-12-14
JP7016129B2 (ja) 2022-02-04
ES2738289T3 (es) 2020-01-21
US11574704B2 (en) 2023-02-07
EP3066215B1 (en) 2019-04-24
JP2017502686A (ja) 2017-01-26
AU2014346788B8 (en) 2021-01-28
EP3594359B1 (en) 2022-05-18
KR20160127713A (ko) 2016-11-04
AU2014346788A8 (en) 2016-06-16
EP3594359A1 (en) 2020-01-15
AU2014346788A1 (en) 2016-05-26
WO2015069790A1 (en) 2015-05-14
US20160283653A1 (en) 2016-09-29
KR102357699B1 (ko) 2022-02-04
JP6657105B2 (ja) 2020-03-04
AU2014346788B2 (en) 2020-09-24
CA2929826C (en) 2022-08-16
WO2015069790A9 (en) 2016-06-02
CA2929826A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
CN106232831B (zh) 通过表达谱分析对淋巴瘤类型进行亚型分类的方法
US10697975B2 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas
US10196691B2 (en) Colon cancer gene expression signatures and methods of use
EP2036987A1 (en) Molecular markers for tumor cell content in tissue samples
KR20070084488A (ko) 고형 종양의 예후 및 치료를 위한 방법 및 시스템
EP3068906A1 (en) Chromosomal assessment to diagnose urogenital malignancy in dogs
EP1683862B1 (en) Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis
US20050287541A1 (en) Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma
WO2017184861A1 (en) Evaluation of mantle cell lymphoma and methods related thereto
AU2007277142B2 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas
Uchida Gene expression profiling for biomarker discovery
EP3638814A1 (en) Method for determining lymphoma type
HK1228459B (en) Method for subtyping lymphoma types by means of expression profiling
HK1228459A1 (en) Method for subtyping lymphoma types by means of expression profiling
NZ612471B2 (en) Colon cancer gene expression signatures and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant